Venmax Drugs & Pharmaceuticals P/E Ratio
Current P/E Ratio
76.32
High Valuation
Very High - High growth expectations or significantly overvalued
Venmax Drugs & Pharmaceuticals P/E ratio. Venmax Drugs & Pharmaceuticals (VENMAX) P/E ratio is 76.32 (High), EPS (TTM) ₹0.21, current price ₹14.44 on BSE — Very High - High growth expectations or significantly overvalued. Check VENMAX company valuation to track the company's total market size over time.
Current Valuation Metrics
P/E Ratio
76.32
Current Price
₹14.44
EPS (TTM)
₹0.21
Exchange
BSE
Valuation Signal
Signal
Overvalued
Sector Context
Sector Average
56.09
Sector Median
31.61
Sector Rank
#11 of 199
Sector Percentile
5.5%
VENMAX P/E Ratio — Valuation Signal & Historical Context
Venmax Drugs & Pharmaceuticals P/E 76.32 — signal: Overvalued. For live price, revenue and the complete fundamental profile, see VENMAX share price screener.
- Stock appears overvalued with PE of 76.32, suggesting caution for new investments
- Trading at premium to sector average PE of 56.09
VENMAX vs Healthcare Peers — P/E Ratio Comparison
Venmax Drugs & Pharmaceuticals P/E 76.32 vs Healthcare average 56.09, median 31.61 — range 2.04–740.29.
Sector Average
56.09
Sector Median
31.61
Lowest P/E
2.04
Highest P/E
740.29
Companies
199
| Company | Symbol | P/E Ratio | Market Cap (₹ Cr) | Valuation |
|---|---|---|---|---|
| Sunrest Lifescience | SUNREST | 2.04 | ₹65 | Low |
| Murae Organisor | MURAE | 2.86 | ₹41 | Low |
| Phaarmasia | PHRMASI | 3.41 | ₹63 | Low |
| Sun Pharma Advanced Rese… | SPARC | 3.98 | ₹6,206 | Low |
| Dipna Pharmachem | DPL | 4.57 | ₹12 | Low |
| JFL Life Sciences | JFLLIFE | 4.88 | ₹66 | Low |
| GKB Ophthalmics | GKB | 5.88 | ₹32 | Low |
| Kabra Drugs | KABRADG | 6.09 | ₹44 | Low |
| Royal Sense | ROYAL | 6.58 | ₹47 | Low |
| Colinz Laboratories | COLINZ | 6.62 | ₹18 | Low |